Publication:
Efficacy and safety of low-concentration, bisulphite-containing, intracameral epinephrine and topical atropine treatments for the prevention of intraoperative floppy iris syndrome

dc.contributor.authorTOKER, AYŞE EBRU
dc.contributor.authorsEsen, Fehim; Bulut, Azer Erdagi; Toker, Ebru
dc.date.accessioned2022-03-12T22:27:02Z
dc.date.accessioned2026-01-10T18:37:22Z
dc.date.available2022-03-12T22:27:02Z
dc.date.issued2018
dc.description.abstractPurpose: The aim of this study was to evaluate the efficacy and safety of topical atropine and topical atropine combined with intracameral low-concentration, bisulphite-containing epinephrine treatment for the prophylaxis of intraoperative floppy iris syndrome.Materials and methods: Seventy-two eyes of 55 male patients who were treated with alpha-adrenergic antagonist medications for benign prostatic hyperplasia were included in this study. Standard premedication with topical cyclopentolate, phenylephrine, tropicamide and ketorolac was applied to all of the patients. In 22 cases no further prophylactic method was used (Group-NP), while in 29 cases topical atropine drops was instilled 12h and 30min before surgery (Group-A) and in 21 cases 1:16000 epinephrine was injected to the anterior chamber at the beginning of surgery (Group-EA) in addition to topical atropine prophylaxis.Results: In Group-NP, 62.8% of the cases developed IFIS, while development of IFIS was significantly lower in Group-A (17.2%, p=0.0004) and Group-EA (9.5%, p<0.0001). Posterior capsule rupture was observed in two cases (9.1%) in Group-NP, in one case (3.4%) in Group-A and was not observed in Group-EA. There was no statistically significant difference between the groups for the development of surgical complications. We did not observe any adverse events or significant endothelial cell loss (p=0.462).Conclusions: Our results indicate that preoperative use of topical atropine reduces the incidence of IFIS. Use of low-concentration, bisulphite-containing epinephrine is more effective in the prevention of IFIS and does not cause preservative related endothelial damage. This prophylaxis may be preferred when preservative free epinephrine is not available.
dc.identifier.doi10.1080/15569527.2018.1456448
dc.identifier.eissn1556-9535
dc.identifier.issn1556-9527
dc.identifier.pubmed29606019
dc.identifier.urihttps://hdl.handle.net/11424/235150
dc.identifier.wosWOS:000438110100013
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofCUTANEOUS AND OCULAR TOXICOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectIntraoperative floppy iris syndrome
dc.subjectepinephrine
dc.subjectatropine
dc.subjectIFIS prophylaxis
dc.subjectcataract surgery
dc.subjectCATARACT-SURGERY
dc.subjectCORNEAL ENDOTHELIUM
dc.subjectTAMSULOSIN
dc.subjectANTAGONISTS
dc.subjectASSOCIATION
dc.subjectPROPHYLAXIS
dc.subjectMANAGEMENT
dc.subjectIFIS
dc.titleEfficacy and safety of low-concentration, bisulphite-containing, intracameral epinephrine and topical atropine treatments for the prevention of intraoperative floppy iris syndrome
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage290
oaire.citation.issue3
oaire.citation.startPage286
oaire.citation.titleCUTANEOUS AND OCULAR TOXICOLOGY
oaire.citation.volume37

Files